Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 17, Issue 17, 2011, Pages 2255-2258

  Williet, Nicolas ^a   Dubreuil, Olivier ^a   Boussaha, Tarek ^a   Trouilloud, Isabelle ^a   Landi, Bruno ^a   Housset, Martin ^a   Botti, Muriel ^a   Rougier, Philippe ^a   Belghiti, Jacques ^b   Taieb, Julien ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

Gemcitabine; Hepatocellular carcinoma; Neoadjuvant therapy; Oxaliplatin; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; GEMCITABINE; INTERFERON; OXALIPLATIN; RIBAVIRIN; SORAFENIB; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ANAMNESIS; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOSCOPIC BIOPSY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PROTEIN BLOOD LEVEL; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 79955793072     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i17.2255     Document Type: Article

References (23)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBO-CAN 2008. Int J Cancer 2010; 127: 2893-2917
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
3. Taïeb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, de Baere T, Mansourbakht T, Delgado MA, Han-noun L, Poynard T, Boige V. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003; 98: 2664-2670
4. Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louaf S S, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008; 112: 2733-2739
5. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taïeb J. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007; 109: 1384-1390
6. Gornet JM, Savier E, Lokiec F, Cvitkovic E, Misset JL, Goldwasser F. Exacerbation of oxaliplatin neurosensory toxicity following surgery. Ann Oncol 2002; 13: 1315-1318
7. Cournede A, Ries P, Richard K, Guillain A, Dahan L, Grandval P, Pourroy B, Moutardier V, Hardwigsen J, Braguer D, Seitz JF. [Oxaliplatin neurotoxicity: a report of three cases with post-operative exacerbation]. Gastroenterol Clin Biol 2005; 29: 461-464
8. Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009; CD001199
9. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004; 5: 409-418
10. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supra-additive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44: 117-123
11. Yang TS, Lin YC, Chen JS, Wang HM, Wang CH. Phase II study of gemcitabine in patients with advanced hepatocellu-lar carcinoma. Cancer 2000; 89: 750-756
12. Berretta M, Lleshi A, di Benedetto F, Bearz A, Spina M, Tirelli U. Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepato-carcinoma HIV/HCV-infected patients. Ann Oncol 2006; 17: 1176-1177
13. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898-1903
14. Boschetti G, Walter T, Hervieu V, Cassier P, Lombard-Bohas C, Adham M, Scoazec JY, Dumortier J. Complete response of hepatocellular carcinoma with systemic combination chemo therapy: not to get out the chemotherapy? Eur J Gastroenterol Hepatol 2010; 22: 1015-1018
15. Bathaix F, Marion D, Cuinet M, Maillard E, Zoulim F, Mornex F, Merle P. Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach. Gastroen-terol Clin Biol 2010; 34: 314-318
16. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62
17. Kerbel RS. Antiangiogenic therapy: a universal chemosensi-tization strategy for cancer? Science 2006; 312: 1171-1175
18. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB. Phase III, randomized study of gem- citabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27: 3778-3785
19. Mima K, Masuda T, Beppu T, Horino K, Komori H, Imsung C, Hayashi H, Okabe H, Takamori H, Baba H. [A long-term survival case of hepatocellular carcinoma with lymph node metastases treated with surgery and radiotherapy]. Gan To Kagaku Ryoho 2008; 35: 2096-2098
20. Lim JH, Lee JW, Kim EJ, Lee JI, Jeong S, Lee DH, Shin YW, Kim JM. [A case of recurred small hepatocellular carcinoma as a solitary lymph node metastasis after hepatic resection]. Korean J Gastroenterol 2007; 50: 66-69
21. Park YJ, Lim do H, Paik SW, Koh KC, Lee JH, Choi MS, Yoo BC, Nam HR, Oh DR, Park W, Ahn YC, Huh SJ. Radiation therapy for abdominal lymph node metastasis from hepato-cellular carcinoma. J Gastroenterol 2006; 41: 1099-1106
22. Yamashita H, Nakagawa K, Shiraishi K, Tago M, Igaki H, Nakamura N, Sasano N, Siina S, Omata M, Ohtomo K. Radiotherapy for lymph node metastases in patients with hepato-cellular carcinoma: retrospective study. J Gastroenterol Hepatol 2007; 22: 523-527
23. Zeng ZC, Tang ZY, Fan J, Qin LX, Ye SL, Zhou J, Sun HC, Wang BL, Wang JH. Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys 2005; 63: 1067-1076